WO2017021871A1 - A cell culture process for modulating glycans - Google Patents
A cell culture process for modulating glycans Download PDFInfo
- Publication number
- WO2017021871A1 WO2017021871A1 PCT/IB2016/054629 IB2016054629W WO2017021871A1 WO 2017021871 A1 WO2017021871 A1 WO 2017021871A1 IB 2016054629 W IB2016054629 W IB 2016054629W WO 2017021871 A1 WO2017021871 A1 WO 2017021871A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell culture
- glycans
- manganese
- cell
- process according
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 48
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000011572 manganese Substances 0.000 claims abstract description 27
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 27
- 239000001963 growth medium Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 48
- 102000003886 Glycoproteins Human genes 0.000 claims description 32
- 108090000288 Glycoproteins Proteins 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 12
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 10
- 230000034994 death Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 150000004676 glycans Chemical group 0.000 description 20
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 7
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 7
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 230000010773 Antigen Neutralization Effects 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000557766 Guthriea Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Definitions
- the present invention relates to the field of cell culture.
- the invention discloses a process for modulating high mannosylated and afucosylated glycans in a glycoprotein composition by supplementing manganese at a specific phase in the growth curve of the cell culture.
- Protein glycosylation is one of the most important post-translation modifications associated with eukaryotic proteins.
- the two major types of glycosylation in eukaryotic cells are N-linked glycosylation, in which glycans are attached to the asparagine of the recognition sequence Asn-X-Thr/Ser, where "X" is any amino acid except proline, and O-linked glycosylation in which glycans are attached to serine or threonine.
- N-linked glycans further are of two types - high mannose type consisting of two N-acetylglucosamines plus a large number of mannose residues (more than 4), and the complex type that contain more than two N- acetylglucosamines plus any number of other types of sugars (galactose, fucose etc).
- N- and O-glycosylation there is normally a range of glycan structures associated with each site (microheterogeneity). Macroheterogeneity results from the fact that not all N-glycan or O- glycan recognition sequences are actually glycosylated. This may be a consequence of the competitive action of diverse enzymes involved in glycosylation and are key to understanding glycoprotein heterogeneity (Marino, K., (2010) Nature Chemical Biology 6,713-723).
- mAbs Recombinant monoclonal antibodies
- mAbs represent the largest and fastest growing group of therapeutic glycoproteins. It has been demonstrated that the structure and composition of the glycan moieties on mAbs can have a profound effect on their safety and efficacy. For e.g. the extent and nature of glycosylation in monoclonal antibodies (mAbs) affects its clearance, immunogenicity, and solubility.
- the efficacy of therapeutic antibodies is mediated by two independent mechanisms, (a) the efficacy resulting from target antigen neutralization or apoptosis and (b) biological activities referred to as antibody effector functions mediated via effector cells or complement system known as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) respectively.
- ADCC antibody-dependent cellular cytotoxicity
- CDC complement-dependent cytotoxicity
- non-fucosylated antibodies include achieving therapeutic efficacy at low doses, inducing high efficacy against tumor cells that express low levels of antigen or triggering high effector function in NK cells with the low-affinity FcyRIIIa allotype for the IgGs (N. Yamane-Ohnuki et al., 2004, Biotechnol Bioeng.;87:614-622 & R. Niwa et al., 2005, Clin Cancer Res.; 11:2327-2336 & R. Niwa et al., 2004 Clin Cancer Res.;10:6248-6255).
- the serum half-life of IgG antibodies is regulated by a number of receptors, including the mannose receptors, which bind both high-mannose-containing pathogens as well as endogenous proteins (Stahl PD. 1992, Curr Opin Immunol. 4:49-52 & Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, Lee YC, Feizi T, Langen H, Nussenzweig MC. 2002. Science. 295:1898-1901). Goetze et al. showed that IgGs containing high- mannose glycans are cleared more rapidly in humans than other glycan forms (Andrew MGoetze et al.
- the components used for modulating a particular glycan content need to be chosen so as to not to affect or significantly alter the amount/level of other glycan content.
- a combination of components, when chosen for modulating or obtaining a specific glycoprofile, should be compatible with each other in yielding the targeted glycan profile without necessarily affecting the titer and/or productivity of the process.
- the objective of the invention is to provide a cell culture process for obtaining a specific glycoprotein composition taking into account several discrete, but inter- linked factors that influence the glycan content of the glycoprotein composition for therapeutic use on one hand and the overall yield of the glycoprotein on other.
- the present invention describes a cell culture process for obtaining a glycoprotein composition comprising high mannosylated and afucosylated glycans, wherein the cell culture process comprises addition of manganese for modulating the amount of high mannose and afucosylated glycans.
- modulation of high mannose and afucosylated glycan content is achieved by adding manganese at a specific phase in the growth curve of the cell culture.
- the invention describes a cell culture process comprising addition of manganese at/during the phase of a cell culture growth curve described as "death phase", to achieve a significant reduction in high mannose and afucosylated glycans content in a glycoprotein composition.
- the inventive method resulting in reduced levels of HM and AF glycans in a glycoprotein composition consequently results in an increase in the ADCC activity of the said glycoprotein composition.
- Figure 1 is a general illustration of cell culture phases showing the lag phase, logarithmic (log) phase, Plateau (or stationary) phase and death (or decline) phase.
- Figure 2 is an illustration of average of percentage of high mannosylated and afucosylated glycans in a glycoprotein composition obtained in no. of batches representative of example I, II and III.
- the error bars represent standard deviation for respective data point.
- Figure 3 represents cell culture progression in terms of viable cell density w.r.t culture age for seven batches illustrating example I.
- the dotted vertical lines represent the cell culture phase where manganese is supplemented.
- Each point in the graph represents average of seven batches and standard deviation among batches is represented as error bars.
- Figure 4 represents cell culture progression in terms of viable cell density w.r.t culture age for four batches illustrating example II.
- the dotted vertical lines represent the cell culture phase where manganese is supplemented. Each point in the graph represents average of four batches and standard deviation among batches is represented as error bars.
- Figure 5 represents cell culture progression in terms of viable cell density w.r.t culture age for three batches illustrating example III.
- the dotted vertical lines represent the cell culture phase where manganese is supplemented. Each point in the graph represents average of three batches and standard deviation among batches is represented as error bars.
- glycocan refers to a monosaccharide or polysaccharide moiety.
- glycoprotein refers to protein or polypeptide having at least one glycan moiety.
- glycoprotein any polypeptide attached to a saccharide moiety is termed as glycoprotein.
- glycoprotein composition refers to an amount typically required for the industrial production of recombinant polypeptides, used for preparation of therapeutically active biopharmaceuticals.
- glycoform or “glycovariant” have been used interchangeably herein, and refers to various oligosaccharide entities or moieties linked in their entirety to the Asparagine 297 (as per Kabat numbering) of the Fc region of the antibody in question, co translationally or post translationally within a host cell.
- M Mannose
- NAG N- N-acetylglucosamine
- F Fucose
- G Galactose
- S Sialic Acid.
- the no. post the letter/letter set indicates no. of respective preceding sugar moiety present in the glycan moiety.
- M3NAG denotes glycan moiety comprising three mannose and one N- N-acetylglucosamine
- the glycan moieties added during the glycosylation process may include M3, M4, M5-8, M3NAG etc. Examples of such glycans and their structures are listed in Table 1. However, Table 1 may in no way be considered to limit the scope of this invention to these glycans.
- the term "glycoprotein or antibody composition" as used herein pertains to the quantity or percentage of different glycoforms present in a glycoprotein or an antibody preparation.
- “Afucosylated glycans” described here consists of glycan moiety wherein fucose is not linked to the non-reducing end of N-acetlyglucosamine.
- examples of afucosylated glycans include M3NAG, GO, G1A, GIB etc.
- Fucosylated glycans described here, consists of glycan moiety wherein fucose which is linked to the non-reducing end of N-acetlyglucosamine.
- examples of fucosylated glycans include M3NAGF, G1AF, G1BF, G2F, G2SF, G2S2F etc.
- High mannosylated glycans described here, consists of comprising glycan moiety which comprises 5 or more mannose residues.
- examples of high mannosylated glycans include M5, M6, M7, M8, M9 etc.
- Table I Representative table of various glycans
- the growth curve of mammalian cells in suspension culture is a sigmoidal plot of cell density as a function of time.
- the growth curve (refer Figure 1) comprises 4 phases, lag, exponential or log, stationary or plateau, and death or decline phase.
- Lag Phase- This is the 1 st phase in the growth curve, characterized by little or no cell division.
- Stationary or Plateau Phase- This is a post-log phase period characterized by slowdown in the division rate, during which cell proliferation is balanced by cell death. As a result there is no resultant increase in the density of the cell culture.
- VCC viable cell count
- IVCD or “Integral viable cell density” refers to area under the viable cell density curve i.e. viable cell density plotted against culture age.
- ADCC Antibody-dependent cell-mediated cytotoxicity
- the present invention discloses a cell culture process for modulating high mannosylated and afucosylated glycans in a glycoprotein composition by supplementing manganese at a specific phase in the growth curve of the cell culture.
- One embodiment of the invention discloses a cell culture process comprising addition of manganese at a specific phase in the growth curve of the cell culture to obtain a glycoprotein composition comprising 5-12% of high mannosylated glycans and 4-8 % of afucosylated glycans.
- Another embodiment of the invention discloses a cell culture process comprising culturing cells in culture medium wherein manganese is supplemented at or during the death phase of cell culture to obtain a glycoprotein composition comprising reduced percentage of mannosylated and afucosylated glycans compared to a cell culture process wherein manganese not so supplemented.
- the cells used are Chinese Hamster Ovary (CHO) cells and the glycoprotein composition obtained is Her-2 antibody composition.
- the said reduction in high mannosylated glycans is in the range of about 35 % to about 50 % and the said reduction in afucosylated glycans is in the range of about 30 % to about 45 %.
- Another embodiment of the invention discloses a cell culture process comprising culturing cells in a culture medium wherein manganese is supplemented at or during the death phase of cell culture to obtain a glycoprotein composition comprising 5- 8% of high mannosylated glycans and 4-5 % of afucosylated glycans.
- the cell culture process comprises culturing cells in a culture medium wherein the cells are inoculated/seeded at a density of 0.4 million cells/ml to 0.6 million cells/ml.
- the cell culture process comprises of culturing cells in a culture medium whereby manganese is supplemented at an IVCD greater than 26, preferably greater than 26 and less than 35.
- the said cell culture process comprises supplementation with about 20 ⁇ of manganese.
- the supplementation of manganese to the cell culture medium can be done either by feeding the cells with a feed comprising manganese or adding manganese separately.
- Examples of useful salts of divalent manganese ions include, but are not limited to, manganese sulphate and manganese chloride.
- the cell culture media that are useful in the application include but are not limited to, the commercially available products PF CHO (HyClone ® ), PowerCHO ® 2 (Lolnza), Zap-CHO (Invitria), CD CHO, CDOptiCHOTM and CHO-S-SFMII (Invitrogen), ProCHOTM (Lonza), CDM4CHOTM (Hyclone), DMEM (Invitrogen), DMEM/F12 (Invitrogen), Ham's F10 (Sigma), Minimal Essential Media (Sigma), and RPMI -1640 (Sigma) and IS CHO-CD G10.3 (Irvine scientific).
- the feed or feed medium in the present invention may be added in a continuous, profile or a bolus mode.
- One or more feeds may be added in one manner (e.g. profile mode), and other feeds in second manner (e.g. bolus or continuous mode).
- the feed may be composed of nutrients or other medium components that have been depleted or metabolized by the cells.
- the feed may be concentrated form of initial cell culture media itself or may be a different culture media.
- the components may include hormones, growth factors, ions vitamins, nucleoside, nucleotides, trace elements, amino acids, lipids or glucose. Supplementary components may be added at one time or in series of additions to replenish the depleted components.
- the feed can be a solution of depleted nutrient(s), mixture of nutrient(s) or a mixture of cell culture medium/feed providing such nutrient(s).
- the cell culture feed that are useful in the invention include but are not limited to, the commercially available products Cell Boost 2 (CB-2, Thermo Scientific Hyclone, Catalogue no SH 30596.03), Cell Boost 4 (CB-4, Thermo Scientific HyClone, Catalog no. SH30928), PF CHO (Thermo Scientific Hyclone, Catalog no. SH30333.3).
- the temperature of a cell culture is selected based on the temperature range at which cells remain viable, produce glycoprotein of interest in desirable quantity and qualitative profiles.
- mammalian cells grow well and produce desirable glycosylation profiles in commercially viable quantity within temperature range of 25°C to 42°C.
- optimum temperature range for CHO cells is at approximately 35°C to 37°C.
- cells may be subjected to temperature shift at any time during the course of the cell culture.
- the temperature shift may be gradual or abrupt.
- the subsequent temperature may be higher or lower than the initial temperature value.
- the cells may be exposed to more than one such temperature shifts.
- the subsequent temperatures may be selected based on the temperature range at which cells remain viable, produce glycoprotein of interest in desirable quantity and quantitative profiles. Those of ordinary skill in the art will be able to choose optimum temperature and/or temperature range depending on the cell type.
- HER-2 antibody was cloned and expressed on a large-scale in fed-batch culture using a CHO cell line as detailed in Molecular Cloning: A laboratory Manual by Green and Sambrook. rCHO cells expressing antibody were seeded at a density of -0.5 million cells/ml in culture media POWER CHO ® 2 (Lonza, Catalog no.: 15- 771) at 35°C and pH of 7.2. Subsequently, feed was added on day 2, 3, 4, 5, and 6. The feed comprises CB4 (CB4, Hyclone, Catalog No.:SH30928.03), betaine and galactose.
- CB4 CB4, Hyclone, Catalog No.:SH30928.03
- the culture medium was supplemented with 20 ⁇ manganese added at varying phases of cell culture i.e at IVCD values of 17-20 (Example I), 26-29 (Example II) and 29-31 (Example III).
- IVCD range in Example I is representative of stationary phase and latter two IVCD ranges (Example II and III) represent the death phase of the cell culture.
- the culture was harvested on day 12 or at viability less than or equal to 60%, whichever was earlier.
- the average percentage of high mannosylated and afucosylated glycans in each of the glycoprotein composition were determined as given in Table II and represented in Figure 1.
- "n" represents the no. of batches performed for a specific experiment /Example. Except for the phase of the cell culture or the IVCD range of manganese addition, the rest of the cell culture conditions including concentration of manganese were kept the same across the batches.
Abstract
The invention describes a cell culture process for modulating percentage of high mannosylated and afucosylated glycans wherein the cell culture process comprises culturing cells in a culture medium and supplementing cell culture with manganese.
Description
A CELL CULTURE PROCESS FOR MODULATING GLYCANS
FIELD OF THE INVENTION
The present invention relates to the field of cell culture. In particular, the invention discloses a process for modulating high mannosylated and afucosylated glycans in a glycoprotein composition by supplementing manganese at a specific phase in the growth curve of the cell culture.
BACKGROUND OF THE INVENTION
Protein glycosylation is one of the most important post-translation modifications associated with eukaryotic proteins. The two major types of glycosylation in eukaryotic cells are N-linked glycosylation, in which glycans are attached to the asparagine of the recognition sequence Asn-X-Thr/Ser, where "X" is any amino acid except proline, and O-linked glycosylation in which glycans are attached to serine or threonine. N-linked glycans further are of two types - high mannose type consisting of two N-acetylglucosamines plus a large number of mannose residues (more than 4), and the complex type that contain more than two N- acetylglucosamines plus any number of other types of sugars (galactose, fucose etc). In both N- and O-glycosylation, there is normally a range of glycan structures associated with each site (microheterogeneity). Macroheterogeneity results from the fact that not all N-glycan or O- glycan recognition sequences are actually glycosylated. This may be a consequence of the competitive action of diverse enzymes involved in glycosylation and are key to understanding glycoprotein heterogeneity (Marino, K., (2010) Nature Chemical Biology 6,713-723).
Recombinant monoclonal antibodies (mAbs) represent the largest and fastest growing group of therapeutic glycoproteins. It has been demonstrated that the structure and composition of the glycan moieties on mAbs can have a profound effect on their safety and efficacy. For e.g. the extent and nature of glycosylation in monoclonal antibodies (mAbs) affects its clearance, immunogenicity, and solubility.
The efficacy of therapeutic antibodies is mediated by two independent mechanisms, (a) the efficacy resulting from target antigen neutralization or apoptosis and (b) biological activities referred to as antibody effector functions mediated via effector cells or complement system known as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) respectively.
Several studies have demonstrated that low fucose levels i.e. higher afucosylated glycoform composition enhance mononuclear cell-mediated antibody-mediated cellular cytotoxicity (ADCC) (Mori K, (2007), Cytotechnology 55(2-3): 109 114. and Shields RL. (2002), J Biol Chem 277(30):26733-26740). Additionally low fucosylation evades the inhibitory effect of serum immunoglobulin G (IgG) on ADCC by its high binding to effector cell receptors (FcyRIIIa) (S. Lida et al., 2006, Clin Cancer Res.; 12:2879-2887). Thus, the advantages of non-fucosylated antibodies include achieving therapeutic efficacy at low doses, inducing high efficacy against tumor cells that express low levels of antigen or triggering high effector function in NK cells with the low-affinity FcyRIIIa allotype for the IgGs (N. Yamane-Ohnuki et al., 2004, Biotechnol Bioeng.;87:614-622 & R. Niwa et al., 2005, Clin Cancer Res.; 11:2327-2336 & R. Niwa et al., 2004 Clin Cancer Res.;10:6248-6255).
However in contrast, Peipp M. et al showed that polymorphonuclear cells preferentially kill via high-fucosylated antibody composition. Further, the same study concluded that high-fucose antibody induced superior ADCC in blood from granulocyte colony-stimulating factor-primed donors containing higher numbers of activated polymorphonuclear cells. (Peipp M et al., Blood. 2008 Sep 15; 112(6):2390-9. doi: 10.1182/blood-2008-03-144600). Further, the efficacy of therapeutic antibodies is also affected by the serum clearance rate i.e. serum half-life of antibodies. The serum half-life of IgG antibodies is regulated by a number of receptors, including the mannose receptors, which bind both high-mannose-containing pathogens as well as endogenous proteins (Stahl PD. 1992, Curr Opin Immunol. 4:49-52 & Lee SJ, Evers S, Roeder
D, Parlow AF, Risteli J, Risteli L, Lee YC, Feizi T, Langen H, Nussenzweig MC. 2002. Science. 295:1898-1901). Goetze et al. showed that IgGs containing high- mannose glycans are cleared more rapidly in humans than other glycan forms (Andrew MGoetze et al. Glycobiology vol. 21 no. 7 pp. 949-959, 2011). Thus, there may be preferential clearance of glycoform bearing the terminal mannose residues which would impact the pharmokinetic profile of an antibody composition. Hence the reduction of high mannose bearing glycoforms improves half-life of an antibody composition which is a desirable quality attribute.
The maintenance and control of specific glycan profile of a glycoprotein is particularly important for the development of a biosimilar. Hence, there is a need for development of cell culture processes for obtaining a 'specific' glycan profile.
The components used for modulating a particular glycan content need to be chosen so as to not to affect or significantly alter the amount/level of other glycan content. In addition, a combination of components, when chosen for modulating or obtaining a specific glycoprofile, should be compatible with each other in yielding the targeted glycan profile without necessarily affecting the titer and/or productivity of the process.
Thus, the objective of the invention is to provide a cell culture process for obtaining a specific glycoprotein composition taking into account several discrete, but inter- linked factors that influence the glycan content of the glycoprotein composition for therapeutic use on one hand and the overall yield of the glycoprotein on other.
SUMMARY OF THE INVENTION
The present invention describes a cell culture process for obtaining a glycoprotein composition comprising high mannosylated and afucosylated glycans, wherein the cell culture process comprises addition of manganese for modulating the amount of high mannose and afucosylated glycans. Particularly, modulation of high mannose and afucosylated glycan content is achieved by adding manganese at a specific phase in the growth curve of the cell culture.
The invention describes a cell culture process comprising addition of manganese at/during the phase of a cell culture growth curve described as "death phase", to achieve a significant reduction in high mannose and afucosylated glycans content in a glycoprotein composition. Delayed addition of manganese viz., at/during death phase or at an IVCD of greater than 26, results in about 50 % reduction in content of high mannose (HM) and afucosylated (AF) glycans compared to the content of HM and AF glycans obtained when manganese not so supplemented.
Specifically, the inventive method resulting in reduced levels of HM and AF glycans in a glycoprotein composition consequently results in an increase in the ADCC activity of the said glycoprotein composition.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a general illustration of cell culture phases showing the lag phase, logarithmic (log) phase, Plateau (or stationary) phase and death (or decline) phase.
Figure 2 is an illustration of average of percentage of high mannosylated and afucosylated glycans in a glycoprotein composition obtained in no. of batches representative of example I, II and III. The error bars represent standard deviation for respective data point.
Figure 3 represents cell culture progression in terms of viable cell density w.r.t culture age for seven batches illustrating example I. The dotted vertical lines represent the cell culture phase where manganese is supplemented. Each point in the graph represents average of seven batches and standard deviation among batches is represented as error bars.
Figure 4 represents cell culture progression in terms of viable cell density w.r.t culture age for four batches illustrating example II. The dotted vertical lines represent the cell culture phase where manganese is supplemented. Each point in the graph represents average of four batches and standard deviation among batches is represented as error bars.
Figure 5 represents cell culture progression in terms of viable cell density w.r.t culture age for three batches illustrating example III. The dotted vertical lines represent the cell culture phase where manganese is supplemented. Each point in the graph represents average of three batches and standard deviation among batches is represented as error bars.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The term "glycan" refers to a monosaccharide or polysaccharide moiety.
The term "glycoprotein" refers to protein or polypeptide having at least one glycan moiety. Thus, any polypeptide attached to a saccharide moiety is termed as glycoprotein.
The term "large-scale production" of glycoprotein composition refers to an amount typically required for the industrial production of recombinant polypeptides, used for preparation of therapeutically active biopharmaceuticals. The term "glycoform" or "glycovariant" have been used interchangeably herein, and refers to various oligosaccharide entities or moieties linked in their entirety to the Asparagine 297 (as per Kabat numbering) of the Fc region of the antibody in question, co translationally or post translationally within a host cell.
The abbreviations used in present invention for denoting the sugars comprising the glycan moieties are: M: Mannose, NAG: N- N-acetylglucosamine, F: Fucose, G: Galactose, S: Sialic Acid. The no. post the letter/letter set indicates no. of respective preceding sugar moiety present in the glycan moiety. For e.g. M3NAG denotes glycan moiety comprising three mannose and one N- N-acetylglucosamine
The glycan moieties added during the glycosylation process may include M3, M4, M5-8, M3NAG etc. Examples of such glycans and their structures are listed in Table 1. However, Table 1 may in no way be considered to limit the scope of this invention to these glycans.
The term "glycoprotein or antibody composition" as used herein pertains to the quantity or percentage of different glycoforms present in a glycoprotein or an antibody preparation.
"Afucosylated glycans" described here, consists of glycan moiety wherein fucose is not linked to the non-reducing end of N-acetlyglucosamine. Without limitation, examples of afucosylated glycans include M3NAG, GO, G1A, GIB etc.
"Fucosylated glycans" described here, consists of glycan moiety wherein fucose which is linked to the non-reducing end of N-acetlyglucosamine. Without limitation, examples of fucosylated glycans include M3NAGF, G1AF, G1BF, G2F, G2SF, G2S2F etc.
"High mannosylated glycans" described here, consists of comprising glycan moiety which comprises 5 or more mannose residues. Without limitation, examples of high mannosylated glycans include M5, M6, M7, M8, M9 etc.
Various methods described in the art such as Wuhrer et. al., Ruhaak L.R., and Geoffrey et. al. can be used for assessing glycovariants present in a glycoprotein composition (Wuhrer M. et al., Journal of Chromatography B, 2005, Vol.825, Issue 2, pages 124-133, Ruhaak L.R., Anal Bioanal Chem, 2010, Vol. 397:3457-3481, Geoffrey, R. G. et. al. Analytical Biochemistry 1996, Vol. 240, pages 210-226).
Table I: Representative table of various glycans
Mannose
N-Acetyl Glucosamine
Galactose
2-AB Label
Fucose
Sialic acid
The growth curve of mammalian cells in suspension culture is a sigmoidal plot of cell density as a function of time. The growth curve (refer Figure 1) comprises 4 phases, lag, exponential or log, stationary or plateau, and death or decline phase.
Lag Phase- This is the 1st phase in the growth curve, characterized by little or no cell division.
Exponential or Log phase- It is a period of active cell proliferation hence the cell density increases exponentially.
Stationary or Plateau Phase- This is a post-log phase period characterized by slowdown in the division rate, during which cell proliferation is balanced by cell death. As a result there is no resultant increase in the density of the cell culture.
Death or Decline Phase- This phase is characterized by excess of cell death over cell proliferation resulting in decline in cell density.
The term "% Viability" refers to percentage of viable cells out of total no. of cells including the viable and non- viable cells at a particular time point in cell culture. The term "Viable cell density (VCD)" refers to the no. of viable cell per unit volume at a particular time point in cell culture. The unit usually used for its measurement is million viable cells/ ml. Graphically, the "VCD profile" represents viable cell count (VCC) over the duration/age of cell culture.
As used herein, "IVCD" or "Integral viable cell density" refers to area under the viable cell density curve i.e. viable cell density plotted against culture age.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a cell-mediated immune defense mechanism whereby a target cell whose membrane- surface antigens have been bound by specific antibodies is lysed by an effector cell of the immune system. In-vitro ADCC assays have been abundantly described in prior art. One such method is modified ADCC method. (Mark Barok et al. Mol Cancer Ther. 2007 Jul; 6(7):2065-72).
Detailed description of the embodiments
The present invention discloses a cell culture process for modulating high mannosylated and afucosylated glycans in a glycoprotein composition by supplementing manganese at a specific phase in the growth curve of the cell culture. One embodiment of the invention discloses a cell culture process comprising addition of manganese at a specific phase in the growth curve of the cell culture to obtain a glycoprotein composition comprising 5-12% of high mannosylated glycans and 4-8 % of afucosylated glycans.
Another embodiment of the invention discloses a cell culture process comprising culturing cells in culture medium wherein manganese is supplemented at or during the death phase of cell culture to obtain a glycoprotein composition comprising reduced percentage of mannosylated and afucosylated glycans compared to a cell culture process wherein manganese not so supplemented.
In any of the above mentioned embodiments, the cells used are Chinese Hamster Ovary (CHO) cells and the glycoprotein composition obtained is Her-2 antibody composition.
In any of the above mentioned embodiments, the said reduction in high mannosylated glycans is in the range of about 35 % to about 50 % and the said reduction in afucosylated glycans is in the range of about 30 % to about 45 %.
Another embodiment of the invention discloses a cell culture process comprising culturing cells in a culture medium wherein manganese is supplemented at or during the death phase of cell culture to obtain a glycoprotein composition comprising 5- 8% of high mannosylated glycans and 4-5 % of afucosylated glycans. In any of the above mentioned embodiments, the cell culture process comprises culturing cells in a culture medium wherein the cells are inoculated/seeded at a density of 0.4 million cells/ml to 0.6 million cells/ml.
In any of the above mentioned embodiments, the cell culture process comprises of culturing cells in a culture medium whereby manganese is supplemented at an IVCD greater than 26, preferably greater than 26 and less than 35.
In any of the above mentioned embodiments of the invention, the said cell culture process comprises supplementation with about 20 μΜ of manganese.
The supplementation of manganese to the cell culture medium can be done either by feeding the cells with a feed comprising manganese or adding manganese separately.
Examples of useful salts of divalent manganese ions include, but are not limited to, manganese sulphate and manganese chloride.
The cell culture media that are useful in the application include but are not limited to, the commercially available products PF CHO (HyClone®), PowerCHO® 2 (Lolnza), Zap-CHO (Invitria), CD CHO, CDOptiCHO™ and CHO-S-SFMII (Invitrogen), ProCHO™ (Lonza), CDM4CHO™ (Hyclone), DMEM (Invitrogen), DMEM/F12 (Invitrogen), Ham's F10 (Sigma), Minimal Essential Media (Sigma), and RPMI -1640 (Sigma) and IS CHO-CD G10.3 (Irvine scientific).
The feed or feed medium in the present invention may be added in a continuous, profile or a bolus mode. One or more feeds may be added in one manner (e.g. profile mode), and other feeds in second manner (e.g. bolus or continuous mode). Further, the feed may be composed of nutrients or other medium components that have been depleted or metabolized by the cells. The feed may be concentrated form of initial cell culture media itself or may be a different culture media. The components may include hormones, growth factors, ions vitamins, nucleoside, nucleotides, trace elements, amino acids, lipids or glucose. Supplementary components may be added at one time or in series of additions to replenish the depleted components. Thus the feed can be a solution of depleted nutrient(s), mixture of nutrient(s) or a mixture of cell culture medium/feed providing such nutrient(s).
The cell culture feed that are useful in the invention include but are not limited to, the commercially available products Cell Boost 2 (CB-2, Thermo Scientific Hyclone, Catalogue no SH 30596.03), Cell Boost 4 (CB-4, Thermo Scientific HyClone, Catalog no. SH30928), PF CHO (Thermo Scientific Hyclone, Catalog no. SH30333.3).
The temperature of a cell culture is selected based on the temperature range at which cells remain viable, produce glycoprotein of interest in desirable quantity and qualitative profiles. In general, mammalian cells grow well and produce desirable glycosylation profiles in commercially viable quantity within temperature range of 25°C to 42°C. For example, optimum temperature range for CHO cells is at approximately 35°C to 37°C. Those of ordinary skill in the art will be able to choose optimum temperature and/or temperature range depending on the cell type.
Optionally, cells may be subjected to temperature shift at any time during the course of the cell culture. The temperature shift may be gradual or abrupt. The subsequent temperature may be higher or lower than the initial temperature value. Additionally, the cells may be exposed to more than one such temperature shifts. As with the initial temperature the subsequent temperatures may be selected based on the temperature range at which cells remain viable, produce glycoprotein of interest in desirable quantity and quantitative profiles. Those of ordinary skill in the art will be able to choose optimum temperature and/or temperature range depending on the cell type.
Certain aspects and embodiments of the invention are more fully defined by reference to the following examples. These examples should not, however, be construed as limiting the scope of the invention. EXAMPLES
HER-2 antibody was cloned and expressed on a large-scale in fed-batch culture using a CHO cell line as detailed in Molecular Cloning: A laboratory Manual by Green and Sambrook. rCHO cells expressing antibody were seeded at a density of
-0.5 million cells/ml in culture media POWER CHO® 2 (Lonza, Catalog no.: 15- 771) at 35°C and pH of 7.2. Subsequently, feed was added on day 2, 3, 4, 5, and 6. The feed comprises CB4 (CB4, Hyclone, Catalog No.:SH30928.03), betaine and galactose. The culture medium was supplemented with 20 μΜ manganese added at varying phases of cell culture i.e at IVCD values of 17-20 (Example I), 26-29 (Example II) and 29-31 (Example III). IVCD range in Example I is representative of stationary phase and latter two IVCD ranges (Example II and III) represent the death phase of the cell culture.
The culture was harvested on day 12 or at viability less than or equal to 60%, whichever was earlier. The average percentage of high mannosylated and afucosylated glycans in each of the glycoprotein composition were determined as given in Table II and represented in Figure 1. "n" represents the no. of batches performed for a specific experiment /Example. Except for the phase of the cell culture or the IVCD range of manganese addition, the rest of the cell culture conditions including concentration of manganese were kept the same across the batches.
Table II: Average Percentage glycans in a glycoprotein composition
Example IVCD % High % Afucosylated
values Mannosylated Glycans
Glycans
I (n=7) 17-20 11.4 7.3
II (n=4) 26-29 7.3 4.9
III (n=3) 29-31 5.4 4.0
Claims
1. A cell culture process comprising addition of manganese to culture media for modulating high mannose and/or afucosylated glycans in a glycoprotein composition.
2. The process according to claim 1, wherein the addition of manganese is during death phase of the cell culture.
3. The process according to claim 1, wherein the addition of manganese is at an IVCD value greater than 26.
4. The process according to claim 1, wherein manganese is added at a concentration of about 20 μΜ.
5. The process according to claim 1, wherein the seeding density for cell culture is about 0.4 million cells/ml to 0.6 million cells/ml.
6. The process according to claim 1, wherein the glycoprotein composition comprises 5-8% of high mannosylated glycans and 4-5 % of afucosylated glycans.
7. The process according to claim 1, wherein the reduction in high mannosylated glycans is in the range of about 35 % to about 50 % and the reduction in afucosylated glycans is in the range of about 30 % to about 45 % in the glycoprotein composition as compared to glycoprotein composition produced otherwise.
8. The process according to claim 1, wherein the cell are CHO cells.
9. The process according to claim 1, wherein the cell culture process comprises temperature shift and/or pH shift.
10. The process according to claim 1, wherein the glycoprotein composition is an anti- HER2 antibody composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4008/CHE/2015 | 2015-08-03 | ||
| IN4008CH2015 | 2015-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017021871A1 true WO2017021871A1 (en) | 2017-02-09 |
Family
ID=57942502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2016/054629 WO2017021871A1 (en) | 2015-08-03 | 2016-08-02 | A cell culture process for modulating glycans |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017021871A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020094694A1 (en) | 2018-11-07 | 2020-05-14 | Richter Gedeon Nyrt. | Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013114245A1 (en) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of glycoprotein composition |
-
2016
- 2016-08-02 WO PCT/IB2016/054629 patent/WO2017021871A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013114245A1 (en) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of glycoprotein composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020094694A1 (en) | 2018-11-07 | 2020-05-14 | Richter Gedeon Nyrt. | Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture |
| JP2022512928A (en) * | 2018-11-07 | 2022-02-07 | リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ | How to modify the glycosylation profile of recombinant glycoproteins produced in cell culture |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10059770B2 (en) | Process of modulating man5 and/or afucosylation content of a glycoprotein composition | |
| WO2015140700A1 (en) | Cell culture process | |
| Konno et al. | Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity | |
| WO2013114164A1 (en) | Method for obtaining glycoprotein composition with increased afucosylation content | |
| WO2013114167A1 (en) | Process of obtaining glycoform composition | |
| EP3036320A1 (en) | Control of protein glycosylation by culture medium supplementation and cell culture process parameters | |
| WO2015128793A1 (en) | A process for modifying high mannose and galactosylation content of a glycoprotein composition | |
| Edwards et al. | Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation | |
| KR20180070553A (en) | Methods for increasing the galactose content of recombinant proteins | |
| US10808272B2 (en) | Method for preparing antibody through regulation of sugar content of antibody | |
| US10590455B2 (en) | Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation | |
| WO2013114165A1 (en) | Process of obtaining glycoprotein composition with increased afucosylation content | |
| CN114990049B (en) | Method for simultaneously regulating glycoform and charge heterogeneity of cell expression product | |
| Seo et al. | Effect of glucose feeding on the glycosylation quality of antibody produced by a human cell line, F2N78, in fed-batch culture | |
| WO2017021871A1 (en) | A cell culture process for modulating glycans | |
| JP6882339B2 (en) | How to modify the protein galactosylation profile of recombinant proteins with peracetyl galactose | |
| US20220098634A1 (en) | Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture | |
| WO2014170866A2 (en) | Process of obtaining glycoprotein composition with increased galactosylation content | |
| CN112074537A (en) | Antibodies with modulated glycan profiles | |
| US20240084355A1 (en) | Cell culture methods | |
| WO2013114240A2 (en) | Method for obtaining a glycoprotein composition | |
| WO2023021532A1 (en) | A process to produce a pharmaceutical composition | |
| Zha et al. | Production of monoclonal antibodies in glycoengineered Pichia pastoris | |
| Goletz et al. | GlycoOptimization for fully human and largely improved biopharmaceutical antibodies and proteins | |
| WO2021066772A1 (en) | Cell culture medium for reducing fucosylation and basic variants in the production of antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16832397 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16832397 Country of ref document: EP Kind code of ref document: A1 |